Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

According to Biocon executive chairperson Kiran Mazumdar-Shaw, the order encourages greater use of generics and biosimilars, areas where India has proven strengths. In an interview with FE ...

said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, adding that one needs to wait for more details on the order to ascertain the full impact. Speaking to CNBC TV18 on May 13 ...

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

the board was of the opinion that we should look at other strategic options which also be includes evaluating a merger," Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in an ...

Biocon and Biocon Biologics Executive Chairperson, Kiran Mazumdar-Shaw, says they're adding capacity at their insulin ...

Trump’s EO on MFN prescription drugs to strengthen adoption of generics & biosimilars: Nandita Vijayasimha, Bengaluru Thursday, May 15, 2025, 08:00 Hrs [IST] US President Donald ...

Upgrad Co-Founder Ronnie Screwvala reshared a post by ex-Indian Olympian Abhinav Bindra on World Mental Health Day. Bindra wrote on X (Twitter), “In the race of life, we often chase gold and glory.

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely ...

“He clearly said that the developed world needs to be equalised,” said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics. “He also said, ‘I want to get rid of the ...